nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—CYP2C9—Capecitabine—colon cancer	0.125	0.441	CbGbCtD
Bicalutamide—CYP2C9—Fluorouracil—colon cancer	0.074	0.262	CbGbCtD
Bicalutamide—CYP3A4—Irinotecan—colon cancer	0.0448	0.158	CbGbCtD
Bicalutamide—AR—scrotum—colon cancer	0.044	0.527	CbGeAlD
Bicalutamide—CYP3A4—Vincristine—colon cancer	0.0392	0.139	CbGbCtD
Bicalutamide—Enzalutamide—ABCB1—colon cancer	0.00735	1	CrCbGaD
Bicalutamide—AR—Regulation of Androgen receptor activity—SPDEF—colon cancer	0.00597	0.101	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDX1—colon cancer	0.00365	0.0617	CbGpPWpGaD
Bicalutamide—AR—epithelium—colon cancer	0.00349	0.0417	CbGeAlD
Bicalutamide—AR—smooth muscle tissue—colon cancer	0.00336	0.0402	CbGeAlD
Bicalutamide—AR—renal system—colon cancer	0.00323	0.0387	CbGeAlD
Bicalutamide—AR—lymphoid tissue—colon cancer	0.00268	0.0321	CbGeAlD
Bicalutamide—AR—digestive system—colon cancer	0.00265	0.0317	CbGeAlD
Bicalutamide—AR—Integrated Breast Cancer Pathway—RAD54L—colon cancer	0.00258	0.0437	CbGpPWpGaD
Bicalutamide—CYP2C19—digestive system—colon cancer	0.00246	0.0294	CbGeAlD
Bicalutamide—AR—vagina—colon cancer	0.00234	0.028	CbGeAlD
Bicalutamide—CYP2C19—vagina—colon cancer	0.00217	0.026	CbGeAlD
Bicalutamide—AR—Nuclear Receptors—HNF4A—colon cancer	0.002	0.0338	CbGpPWpGaD
Bicalutamide—AR—liver—colon cancer	0.00198	0.0236	CbGeAlD
Bicalutamide—CYP2C9—digestive system—colon cancer	0.0019	0.0228	CbGeAlD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—AXIN2—colon cancer	0.00187	0.0316	CbGpPWpGaD
Bicalutamide—CYP2C19—liver—colon cancer	0.00183	0.0219	CbGeAlD
Bicalutamide—CYP3A4—renal system—colon cancer	0.00177	0.0212	CbGeAlD
Bicalutamide—CYP2D6—renal system—colon cancer	0.00174	0.0209	CbGeAlD
Bicalutamide—CYP2D6—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.00166	0.0282	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptor transcription pathway—HNF4A—colon cancer	0.00158	0.0267	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—ODC1—colon cancer	0.00156	0.0265	CbGpPWpGaD
Bicalutamide—AR—lymph node—colon cancer	0.00151	0.0181	CbGeAlD
Bicalutamide—CYP3A4—digestive system—colon cancer	0.00145	0.0174	CbGeAlD
Bicalutamide—CYP2D6—digestive system—colon cancer	0.00143	0.0171	CbGeAlD
Bicalutamide—CYP2C9—liver—colon cancer	0.00142	0.017	CbGeAlD
Bicalutamide—CYP2C19—Metapathway biotransformation—CHST4—colon cancer	0.00126	0.0214	CbGpPWpGaD
Bicalutamide—Asthma—Capecitabine—colon cancer	0.00123	0.00217	CcSEcCtD
Bicalutamide—Dysphagia—Capecitabine—colon cancer	0.00123	0.00217	CcSEcCtD
Bicalutamide—Thrombophlebitis—Methotrexate—colon cancer	0.00123	0.00216	CcSEcCtD
Bicalutamide—Diabetes mellitus—Methotrexate—colon cancer	0.00122	0.00215	CcSEcCtD
Bicalutamide—Anaemia—Vincristine—colon cancer	0.00122	0.00215	CcSEcCtD
Bicalutamide—Angina pectoris—Capecitabine—colon cancer	0.0012	0.00212	CcSEcCtD
Bicalutamide—Anaemia—Irinotecan—colon cancer	0.00119	0.00209	CcSEcCtD
Bicalutamide—Bronchitis—Capecitabine—colon cancer	0.00119	0.00209	CcSEcCtD
Bicalutamide—Hepatic failure—Methotrexate—colon cancer	0.00118	0.00208	CcSEcCtD
Bicalutamide—CYP2D6—Metapathway biotransformation—CHST4—colon cancer	0.00116	0.0197	CbGpPWpGaD
Bicalutamide—Neutropenia—Capecitabine—colon cancer	0.00115	0.00203	CcSEcCtD
Bicalutamide—Dysuria—Capecitabine—colon cancer	0.00115	0.00203	CcSEcCtD
Bicalutamide—CYP2C9—Metapathway biotransformation—CHST4—colon cancer	0.00115	0.0195	CbGpPWpGaD
Bicalutamide—Syncope—Irinotecan—colon cancer	0.00115	0.00203	CcSEcCtD
Bicalutamide—Hypertension—Vincristine—colon cancer	0.00114	0.00201	CcSEcCtD
Bicalutamide—Anaemia—Fluorouracil—colon cancer	0.00114	0.002	CcSEcCtD
Bicalutamide—Loss of consciousness—Irinotecan—colon cancer	0.00113	0.00199	CcSEcCtD
Bicalutamide—Myalgia—Vincristine—colon cancer	0.00112	0.00198	CcSEcCtD
Bicalutamide—Weight increased—Capecitabine—colon cancer	0.00112	0.00198	CcSEcCtD
Bicalutamide—Cough—Irinotecan—colon cancer	0.00112	0.00197	CcSEcCtD
Bicalutamide—Weight decreased—Capecitabine—colon cancer	0.00112	0.00197	CcSEcCtD
Bicalutamide—Hyperglycaemia—Capecitabine—colon cancer	0.00111	0.00196	CcSEcCtD
Bicalutamide—Hypertension—Irinotecan—colon cancer	0.00111	0.00195	CcSEcCtD
Bicalutamide—Pneumonia—Capecitabine—colon cancer	0.00111	0.00195	CcSEcCtD
Bicalutamide—Depression—Capecitabine—colon cancer	0.0011	0.00193	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—HNF4A—colon cancer	0.00109	0.0184	CbGpPWpGaD
Bicalutamide—CYP3A4—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.00109	0.0184	CbGpPWpGaD
Bicalutamide—Acute coronary syndrome—Capecitabine—colon cancer	0.00108	0.00191	CcSEcCtD
Bicalutamide—Cerebrovascular accident—Methotrexate—colon cancer	0.00108	0.00191	CcSEcCtD
Bicalutamide—CYP3A4—liver—colon cancer	0.00108	0.0129	CbGeAlD
Bicalutamide—Neuropathy peripheral—Capecitabine—colon cancer	0.00108	0.0019	CcSEcCtD
Bicalutamide—Myocardial infarction—Capecitabine—colon cancer	0.00108	0.0019	CcSEcCtD
Bicalutamide—Oedema—Vincristine—colon cancer	0.00108	0.0019	CcSEcCtD
Bicalutamide—Jaundice—Capecitabine—colon cancer	0.00107	0.00189	CcSEcCtD
Bicalutamide—Infection—Vincristine—colon cancer	0.00107	0.00188	CcSEcCtD
Bicalutamide—Conjunctivitis—Capecitabine—colon cancer	0.00107	0.00188	CcSEcCtD
Bicalutamide—Urinary tract infection—Capecitabine—colon cancer	0.00107	0.00188	CcSEcCtD
Bicalutamide—CYP2D6—liver—colon cancer	0.00106	0.0127	CbGeAlD
Bicalutamide—Confusional state—Irinotecan—colon cancer	0.00106	0.00186	CcSEcCtD
Bicalutamide—Nervous system disorder—Vincristine—colon cancer	0.00105	0.00186	CcSEcCtD
Bicalutamide—Thrombocytopenia—Vincristine—colon cancer	0.00105	0.00186	CcSEcCtD
Bicalutamide—Haematuria—Capecitabine—colon cancer	0.00105	0.00185	CcSEcCtD
Bicalutamide—Oedema—Irinotecan—colon cancer	0.00105	0.00185	CcSEcCtD
Bicalutamide—Myalgia—Fluorouracil—colon cancer	0.00105	0.00185	CcSEcCtD
Bicalutamide—Chest pain—Fluorouracil—colon cancer	0.00105	0.00185	CcSEcCtD
Bicalutamide—Infection—Irinotecan—colon cancer	0.00104	0.00183	CcSEcCtD
Bicalutamide—Hyperhidrosis—Vincristine—colon cancer	0.00104	0.00183	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Capecitabine—colon cancer	0.00104	0.00183	CcSEcCtD
Bicalutamide—Epistaxis—Capecitabine—colon cancer	0.00104	0.00183	CcSEcCtD
Bicalutamide—Shock—Irinotecan—colon cancer	0.00103	0.00182	CcSEcCtD
Bicalutamide—Nervous system disorder—Irinotecan—colon cancer	0.00103	0.00181	CcSEcCtD
Bicalutamide—Thrombocytopenia—Irinotecan—colon cancer	0.00103	0.00181	CcSEcCtD
Bicalutamide—Anorexia—Vincristine—colon cancer	0.00103	0.00181	CcSEcCtD
Bicalutamide—Hyperhidrosis—Irinotecan—colon cancer	0.00101	0.00179	CcSEcCtD
Bicalutamide—Confusional state—Fluorouracil—colon cancer	0.00101	0.00178	CcSEcCtD
Bicalutamide—Bradycardia—Capecitabine—colon cancer	0.001	0.00177	CcSEcCtD
Bicalutamide—Oedema—Fluorouracil—colon cancer	0.001	0.00177	CcSEcCtD
Bicalutamide—Anorexia—Irinotecan—colon cancer	0.000999	0.00176	CcSEcCtD
Bicalutamide—Infection—Fluorouracil—colon cancer	0.000997	0.00176	CcSEcCtD
Bicalutamide—Haemoglobin—Capecitabine—colon cancer	0.000992	0.00175	CcSEcCtD
Bicalutamide—Rhinitis—Capecitabine—colon cancer	0.000989	0.00174	CcSEcCtD
Bicalutamide—Haemorrhage—Capecitabine—colon cancer	0.000987	0.00174	CcSEcCtD
Bicalutamide—Nervous system disorder—Fluorouracil—colon cancer	0.000984	0.00173	CcSEcCtD
Bicalutamide—Thrombocytopenia—Fluorouracil—colon cancer	0.000982	0.00173	CcSEcCtD
Bicalutamide—Liver function test abnormal—Methotrexate—colon cancer	0.00098	0.00173	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Vincristine—colon cancer	0.00098	0.00173	CcSEcCtD
Bicalutamide—Pharyngitis—Capecitabine—colon cancer	0.000979	0.00173	CcSEcCtD
Bicalutamide—Urinary tract disorder—Capecitabine—colon cancer	0.000975	0.00172	CcSEcCtD
Bicalutamide—Insomnia—Vincristine—colon cancer	0.000973	0.00172	CcSEcCtD
Bicalutamide—Oedema peripheral—Capecitabine—colon cancer	0.000972	0.00171	CcSEcCtD
Bicalutamide—Urethral disorder—Capecitabine—colon cancer	0.000967	0.00171	CcSEcCtD
Bicalutamide—Paraesthesia—Vincristine—colon cancer	0.000966	0.0017	CcSEcCtD
Bicalutamide—Breast disorder—Methotrexate—colon cancer	0.00096	0.00169	CcSEcCtD
Bicalutamide—Anorexia—Fluorouracil—colon cancer	0.000956	0.00169	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.000955	0.0162	CbGpPWpGaD
Bicalutamide—Visual impairment—Capecitabine—colon cancer	0.000951	0.00168	CcSEcCtD
Bicalutamide—Insomnia—Irinotecan—colon cancer	0.000947	0.00167	CcSEcCtD
Bicalutamide—Paraesthesia—Irinotecan—colon cancer	0.000941	0.00166	CcSEcCtD
Bicalutamide—Decreased appetite—Vincristine—colon cancer	0.000935	0.00165	CcSEcCtD
Bicalutamide—Dyspnoea—Irinotecan—colon cancer	0.000934	0.00165	CcSEcCtD
Bicalutamide—Somnolence—Irinotecan—colon cancer	0.000931	0.00164	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Vincristine—colon cancer	0.000929	0.00164	CcSEcCtD
Bicalutamide—Fatigue—Vincristine—colon cancer	0.000927	0.00164	CcSEcCtD
Bicalutamide—Dyspepsia—Irinotecan—colon cancer	0.000922	0.00163	CcSEcCtD
Bicalutamide—Pain—Vincristine—colon cancer	0.00092	0.00162	CcSEcCtD
Bicalutamide—Constipation—Vincristine—colon cancer	0.00092	0.00162	CcSEcCtD
Bicalutamide—Asthma—Methotrexate—colon cancer	0.000918	0.00162	CcSEcCtD
Bicalutamide—Cardiac disorder—Capecitabine—colon cancer	0.000916	0.00161	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000914	0.00161	CcSEcCtD
Bicalutamide—Decreased appetite—Irinotecan—colon cancer	0.000911	0.00161	CcSEcCtD
Bicalutamide—Eosinophilia—Methotrexate—colon cancer	0.000909	0.0016	CcSEcCtD
Bicalutamide—Insomnia—Fluorouracil—colon cancer	0.000907	0.0016	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Irinotecan—colon cancer	0.000904	0.00159	CcSEcCtD
Bicalutamide—Fatigue—Irinotecan—colon cancer	0.000903	0.00159	CcSEcCtD
Bicalutamide—Paraesthesia—Fluorouracil—colon cancer	0.000901	0.00159	CcSEcCtD
Bicalutamide—Constipation—Irinotecan—colon cancer	0.000896	0.00158	CcSEcCtD
Bicalutamide—Pain—Irinotecan—colon cancer	0.000896	0.00158	CcSEcCtD
Bicalutamide—Angiopathy—Capecitabine—colon cancer	0.000895	0.00158	CcSEcCtD
Bicalutamide—Dyspnoea—Fluorouracil—colon cancer	0.000894	0.00158	CcSEcCtD
Bicalutamide—Somnolence—Fluorouracil—colon cancer	0.000892	0.00157	CcSEcCtD
Bicalutamide—Immune system disorder—Capecitabine—colon cancer	0.000891	0.00157	CcSEcCtD
Bicalutamide—Mediastinal disorder—Capecitabine—colon cancer	0.000889	0.00157	CcSEcCtD
Bicalutamide—Chills—Capecitabine—colon cancer	0.000885	0.00156	CcSEcCtD
Bicalutamide—Dyspepsia—Fluorouracil—colon cancer	0.000883	0.00156	CcSEcCtD
Bicalutamide—Arrhythmia—Capecitabine—colon cancer	0.000882	0.00155	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Vincristine—colon cancer	0.00088	0.00155	CcSEcCtD
Bicalutamide—Decreased appetite—Fluorouracil—colon cancer	0.000872	0.00154	CcSEcCtD
Bicalutamide—Alopecia—Capecitabine—colon cancer	0.000872	0.00154	CcSEcCtD
Bicalutamide—AR—Nuclear Receptors—PPARG—colon cancer	0.000867	0.0147	CbGpPWpGaD
Bicalutamide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000866	0.00153	CcSEcCtD
Bicalutamide—Mental disorder—Capecitabine—colon cancer	0.000865	0.00152	CcSEcCtD
Bicalutamide—Feeling abnormal—Irinotecan—colon cancer	0.000863	0.00152	CcSEcCtD
Bicalutamide—Malnutrition—Capecitabine—colon cancer	0.000859	0.00151	CcSEcCtD
Bicalutamide—Dysuria—Methotrexate—colon cancer	0.000858	0.00151	CcSEcCtD
Bicalutamide—Neutropenia—Methotrexate—colon cancer	0.000858	0.00151	CcSEcCtD
Bicalutamide—Pain—Fluorouracil—colon cancer	0.000858	0.00151	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Irinotecan—colon cancer	0.000857	0.00151	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MSH6—colon cancer	0.000852	0.0144	CbGpPWpGaD
Bicalutamide—Abdominal pain—Vincristine—colon cancer	0.00085	0.0015	CcSEcCtD
Bicalutamide—Body temperature increased—Vincristine—colon cancer	0.00085	0.0015	CcSEcCtD
Bicalutamide—Flatulence—Capecitabine—colon cancer	0.000847	0.00149	CcSEcCtD
Bicalutamide—Erectile dysfunction—Methotrexate—colon cancer	0.000845	0.00149	CcSEcCtD
Bicalutamide—Back pain—Capecitabine—colon cancer	0.000831	0.00147	CcSEcCtD
Bicalutamide—Abdominal pain—Irinotecan—colon cancer	0.000828	0.00146	CcSEcCtD
Bicalutamide—Body temperature increased—Irinotecan—colon cancer	0.000828	0.00146	CcSEcCtD
Bicalutamide—Feeling abnormal—Fluorouracil—colon cancer	0.000827	0.00146	CcSEcCtD
Bicalutamide—Muscle spasms—Capecitabine—colon cancer	0.000826	0.00146	CcSEcCtD
Bicalutamide—Pneumonia—Methotrexate—colon cancer	0.000823	0.00145	CcSEcCtD
Bicalutamide—Depression—Methotrexate—colon cancer	0.000816	0.00144	CcSEcCtD
Bicalutamide—Urticaria—Fluorouracil—colon cancer	0.000797	0.00141	CcSEcCtD
Bicalutamide—Conjunctivitis—Methotrexate—colon cancer	0.000795	0.0014	CcSEcCtD
Bicalutamide—Anaemia—Capecitabine—colon cancer	0.000794	0.0014	CcSEcCtD
Bicalutamide—Body temperature increased—Fluorouracil—colon cancer	0.000793	0.0014	CcSEcCtD
Bicalutamide—Hypersensitivity—Vincristine—colon cancer	0.000793	0.0014	CcSEcCtD
Bicalutamide—Sweating—Methotrexate—colon cancer	0.000785	0.00138	CcSEcCtD
Bicalutamide—Haematuria—Methotrexate—colon cancer	0.00078	0.00138	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Methotrexate—colon cancer	0.000774	0.00136	CcSEcCtD
Bicalutamide—Epistaxis—Methotrexate—colon cancer	0.000772	0.00136	CcSEcCtD
Bicalutamide—Hypersensitivity—Irinotecan—colon cancer	0.000772	0.00136	CcSEcCtD
Bicalutamide—Asthenia—Vincristine—colon cancer	0.000772	0.00136	CcSEcCtD
Bicalutamide—Syncope—Capecitabine—colon cancer	0.00077	0.00136	CcSEcCtD
Bicalutamide—CYP3A4—Metapathway biotransformation—CHST4—colon cancer	0.00076	0.0129	CbGpPWpGaD
Bicalutamide—Loss of consciousness—Capecitabine—colon cancer	0.000755	0.00133	CcSEcCtD
Bicalutamide—Asthenia—Irinotecan—colon cancer	0.000752	0.00133	CcSEcCtD
Bicalutamide—Cough—Capecitabine—colon cancer	0.00075	0.00132	CcSEcCtD
Bicalutamide—Hypertension—Capecitabine—colon cancer	0.000742	0.00131	CcSEcCtD
Bicalutamide—Hypersensitivity—Fluorouracil—colon cancer	0.000739	0.0013	CcSEcCtD
Bicalutamide—Haemoglobin—Methotrexate—colon cancer	0.000738	0.0013	CcSEcCtD
Bicalutamide—Diarrhoea—Vincristine—colon cancer	0.000736	0.0013	CcSEcCtD
Bicalutamide—Haemorrhage—Methotrexate—colon cancer	0.000735	0.0013	CcSEcCtD
Bicalutamide—Myalgia—Capecitabine—colon cancer	0.000731	0.00129	CcSEcCtD
Bicalutamide—Chest pain—Capecitabine—colon cancer	0.000731	0.00129	CcSEcCtD
Bicalutamide—Pharyngitis—Methotrexate—colon cancer	0.000729	0.00129	CcSEcCtD
Bicalutamide—Anxiety—Capecitabine—colon cancer	0.000729	0.00129	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000726	0.00128	CcSEcCtD
Bicalutamide—Urinary tract disorder—Methotrexate—colon cancer	0.000726	0.00128	CcSEcCtD
Bicalutamide—Urethral disorder—Methotrexate—colon cancer	0.00072	0.00127	CcSEcCtD
Bicalutamide—Diarrhoea—Irinotecan—colon cancer	0.000717	0.00126	CcSEcCtD
Bicalutamide—Dry mouth—Capecitabine—colon cancer	0.000715	0.00126	CcSEcCtD
Bicalutamide—Dizziness—Vincristine—colon cancer	0.000711	0.00125	CcSEcCtD
Bicalutamide—Pruritus—Fluorouracil—colon cancer	0.00071	0.00125	CcSEcCtD
Bicalutamide—Visual impairment—Methotrexate—colon cancer	0.000708	0.00125	CcSEcCtD
Bicalutamide—Confusional state—Capecitabine—colon cancer	0.000707	0.00125	CcSEcCtD
Bicalutamide—Oedema—Capecitabine—colon cancer	0.000701	0.00124	CcSEcCtD
Bicalutamide—Infection—Capecitabine—colon cancer	0.000697	0.00123	CcSEcCtD
Bicalutamide—Dizziness—Irinotecan—colon cancer	0.000693	0.00122	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MSH2—colon cancer	0.000691	0.0117	CbGpPWpGaD
Bicalutamide—Shock—Capecitabine—colon cancer	0.00069	0.00122	CcSEcCtD
Bicalutamide—Nervous system disorder—Capecitabine—colon cancer	0.000688	0.00121	CcSEcCtD
Bicalutamide—Diarrhoea—Fluorouracil—colon cancer	0.000686	0.00121	CcSEcCtD
Bicalutamide—Thrombocytopenia—Capecitabine—colon cancer	0.000686	0.00121	CcSEcCtD
Bicalutamide—AR—Nuclear Receptor transcription pathway—PPARG—colon cancer	0.000685	0.0116	CbGpPWpGaD
Bicalutamide—Vomiting—Vincristine—colon cancer	0.000684	0.00121	CcSEcCtD
Bicalutamide—Cardiac disorder—Methotrexate—colon cancer	0.000682	0.0012	CcSEcCtD
Bicalutamide—Skin disorder—Capecitabine—colon cancer	0.000681	0.0012	CcSEcCtD
Bicalutamide—Rash—Vincristine—colon cancer	0.000678	0.0012	CcSEcCtD
Bicalutamide—Hyperhidrosis—Capecitabine—colon cancer	0.000678	0.0012	CcSEcCtD
Bicalutamide—Dermatitis—Vincristine—colon cancer	0.000678	0.00119	CcSEcCtD
Bicalutamide—Headache—Vincristine—colon cancer	0.000674	0.00119	CcSEcCtD
Bicalutamide—Anorexia—Capecitabine—colon cancer	0.000668	0.00118	CcSEcCtD
Bicalutamide—Angiopathy—Methotrexate—colon cancer	0.000667	0.00118	CcSEcCtD
Bicalutamide—Vomiting—Irinotecan—colon cancer	0.000666	0.00117	CcSEcCtD
Bicalutamide—Immune system disorder—Methotrexate—colon cancer	0.000664	0.00117	CcSEcCtD
Bicalutamide—Dizziness—Fluorouracil—colon cancer	0.000663	0.00117	CcSEcCtD
Bicalutamide—Mediastinal disorder—Methotrexate—colon cancer	0.000662	0.00117	CcSEcCtD
Bicalutamide—Rash—Irinotecan—colon cancer	0.000661	0.00116	CcSEcCtD
Bicalutamide—Dermatitis—Irinotecan—colon cancer	0.00066	0.00116	CcSEcCtD
Bicalutamide—Chills—Methotrexate—colon cancer	0.000659	0.00116	CcSEcCtD
Bicalutamide—Headache—Irinotecan—colon cancer	0.000656	0.00116	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.000652	0.011	CbGpPWpGaD
Bicalutamide—AR—Nongenotropic Androgen signaling—SRC—colon cancer	0.000649	0.011	CbGpPWpGaD
Bicalutamide—Alopecia—Methotrexate—colon cancer	0.000649	0.00114	CcSEcCtD
Bicalutamide—Mental disorder—Methotrexate—colon cancer	0.000644	0.00113	CcSEcCtD
Bicalutamide—Malnutrition—Methotrexate—colon cancer	0.00064	0.00113	CcSEcCtD
Bicalutamide—Nausea—Vincristine—colon cancer	0.000639	0.00113	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000639	0.00113	CcSEcCtD
Bicalutamide—Vomiting—Fluorouracil—colon cancer	0.000638	0.00112	CcSEcCtD
Bicalutamide—Insomnia—Capecitabine—colon cancer	0.000634	0.00112	CcSEcCtD
Bicalutamide—Rash—Fluorouracil—colon cancer	0.000633	0.00112	CcSEcCtD
Bicalutamide—Dermatitis—Fluorouracil—colon cancer	0.000632	0.00111	CcSEcCtD
Bicalutamide—Paraesthesia—Capecitabine—colon cancer	0.00063	0.00111	CcSEcCtD
Bicalutamide—Headache—Fluorouracil—colon cancer	0.000629	0.00111	CcSEcCtD
Bicalutamide—Dyspnoea—Capecitabine—colon cancer	0.000625	0.0011	CcSEcCtD
Bicalutamide—Nausea—Irinotecan—colon cancer	0.000622	0.0011	CcSEcCtD
Bicalutamide—Back pain—Methotrexate—colon cancer	0.000619	0.00109	CcSEcCtD
Bicalutamide—Dyspepsia—Capecitabine—colon cancer	0.000617	0.00109	CcSEcCtD
Bicalutamide—Decreased appetite—Capecitabine—colon cancer	0.000609	0.00107	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Capecitabine—colon cancer	0.000605	0.00107	CcSEcCtD
Bicalutamide—Fatigue—Capecitabine—colon cancer	0.000604	0.00107	CcSEcCtD
Bicalutamide—Pain—Capecitabine—colon cancer	0.0006	0.00106	CcSEcCtD
Bicalutamide—Constipation—Capecitabine—colon cancer	0.0006	0.00106	CcSEcCtD
Bicalutamide—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000597	0.0101	CbGpPWpGaD
Bicalutamide—Nausea—Fluorouracil—colon cancer	0.000596	0.00105	CcSEcCtD
Bicalutamide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000596	0.0101	CbGpPWpGaD
Bicalutamide—Anaemia—Methotrexate—colon cancer	0.000591	0.00104	CcSEcCtD
Bicalutamide—CYP2C19—Metapathway biotransformation—CHST5—colon cancer	0.00058	0.00982	CbGpPWpGaD
Bicalutamide—Feeling abnormal—Capecitabine—colon cancer	0.000578	0.00102	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Capecitabine—colon cancer	0.000573	0.00101	CcSEcCtD
Bicalutamide—Cough—Methotrexate—colon cancer	0.000558	0.000984	CcSEcCtD
Bicalutamide—Urticaria—Capecitabine—colon cancer	0.000557	0.000982	CcSEcCtD
Bicalutamide—Abdominal pain—Capecitabine—colon cancer	0.000554	0.000977	CcSEcCtD
Bicalutamide—Body temperature increased—Capecitabine—colon cancer	0.000554	0.000977	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.000549	0.00928	CbGpPWpGaD
Bicalutamide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000544	0.00921	CbGpPWpGaD
Bicalutamide—Chest pain—Methotrexate—colon cancer	0.000544	0.00096	CcSEcCtD
Bicalutamide—Myalgia—Methotrexate—colon cancer	0.000544	0.00096	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000541	0.000953	CcSEcCtD
Bicalutamide—CYP2D6—Metapathway biotransformation—CHST5—colon cancer	0.000534	0.00903	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CHST5—colon cancer	0.000529	0.00895	CbGpPWpGaD
Bicalutamide—Confusional state—Methotrexate—colon cancer	0.000526	0.000928	CcSEcCtD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000519	0.00877	CbGpPWpGaD
Bicalutamide—Infection—Methotrexate—colon cancer	0.000519	0.000914	CcSEcCtD
Bicalutamide—Hypersensitivity—Capecitabine—colon cancer	0.000517	0.000911	CcSEcCtD
Bicalutamide—Nervous system disorder—Methotrexate—colon cancer	0.000512	0.000902	CcSEcCtD
Bicalutamide—Thrombocytopenia—Methotrexate—colon cancer	0.000511	0.000901	CcSEcCtD
Bicalutamide—Skin disorder—Methotrexate—colon cancer	0.000507	0.000894	CcSEcCtD
Bicalutamide—Hyperhidrosis—Methotrexate—colon cancer	0.000505	0.00089	CcSEcCtD
Bicalutamide—AR—FOXA1 transcription factor network—EP300—colon cancer	0.000505	0.00853	CbGpPWpGaD
Bicalutamide—Asthenia—Capecitabine—colon cancer	0.000503	0.000887	CcSEcCtD
Bicalutamide—CYP3A4—Irinotecan Pathway—APC—colon cancer	0.000501	0.00848	CbGpPWpGaD
Bicalutamide—Anorexia—Methotrexate—colon cancer	0.000498	0.000877	CcSEcCtD
Bicalutamide—Pruritus—Capecitabine—colon cancer	0.000496	0.000875	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—APC—colon cancer	0.000495	0.00838	CbGpPWpGaD
Bicalutamide—AR—Nongenotropic Androgen signaling—PIK3CA—colon cancer	0.000494	0.00835	CbGpPWpGaD
Bicalutamide—Diarrhoea—Capecitabine—colon cancer	0.00048	0.000846	CcSEcCtD
Bicalutamide—AR—Notch-mediated HES/HEY network—EP300—colon cancer	0.000479	0.0081	CbGpPWpGaD
Bicalutamide—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000476	0.000838	CcSEcCtD
Bicalutamide—Insomnia—Methotrexate—colon cancer	0.000472	0.000832	CcSEcCtD
Bicalutamide—Paraesthesia—Methotrexate—colon cancer	0.000469	0.000826	CcSEcCtD
Bicalutamide—Dyspnoea—Methotrexate—colon cancer	0.000465	0.00082	CcSEcCtD
Bicalutamide—Somnolence—Methotrexate—colon cancer	0.000464	0.000818	CcSEcCtD
Bicalutamide—Dizziness—Capecitabine—colon cancer	0.000464	0.000817	CcSEcCtD
Bicalutamide—Dyspepsia—Methotrexate—colon cancer	0.000459	0.00081	CcSEcCtD
Bicalutamide—AR—Nongenotropic Androgen signaling—HRAS—colon cancer	0.000457	0.00773	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—colon cancer	0.000456	0.00771	CbGpPWpGaD
Bicalutamide—Decreased appetite—Methotrexate—colon cancer	0.000454	0.0008	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Methotrexate—colon cancer	0.000451	0.000794	CcSEcCtD
Bicalutamide—Fatigue—Methotrexate—colon cancer	0.00045	0.000793	CcSEcCtD
Bicalutamide—Pain—Methotrexate—colon cancer	0.000446	0.000787	CcSEcCtD
Bicalutamide—Vomiting—Capecitabine—colon cancer	0.000446	0.000786	CcSEcCtD
Bicalutamide—Rash—Capecitabine—colon cancer	0.000442	0.000779	CcSEcCtD
Bicalutamide—Dermatitis—Capecitabine—colon cancer	0.000442	0.000779	CcSEcCtD
Bicalutamide—Headache—Capecitabine—colon cancer	0.000439	0.000774	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000439	0.00742	CbGpPWpGaD
Bicalutamide—AR—Regulation of Androgen receptor activity—EP300—colon cancer	0.000435	0.00735	CbGpPWpGaD
Bicalutamide—Feeling abnormal—Methotrexate—colon cancer	0.00043	0.000758	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Methotrexate—colon cancer	0.000427	0.000753	CcSEcCtD
Bicalutamide—AR—Regulation of Androgen receptor activity—SRC—colon cancer	0.000423	0.00715	CbGpPWpGaD
Bicalutamide—AR—Coregulation of Androgen receptor activity—CCND1—colon cancer	0.000422	0.00714	CbGpPWpGaD
Bicalutamide—AR—Coregulation of Androgen receptor activity—CTNNB1—colon cancer	0.000418	0.00707	CbGpPWpGaD
Bicalutamide—Nausea—Capecitabine—colon cancer	0.000416	0.000734	CcSEcCtD
Bicalutamide—Urticaria—Methotrexate—colon cancer	0.000415	0.000731	CcSEcCtD
Bicalutamide—Body temperature increased—Methotrexate—colon cancer	0.000413	0.000727	CcSEcCtD
Bicalutamide—Abdominal pain—Methotrexate—colon cancer	0.000413	0.000727	CcSEcCtD
Bicalutamide—AR—Nongenotropic Androgen signaling—AKT1—colon cancer	0.000403	0.00682	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—BAX—colon cancer	0.000391	0.00661	CbGpPWpGaD
Bicalutamide—Hypersensitivity—Methotrexate—colon cancer	0.000385	0.000678	CcSEcCtD
Bicalutamide—Asthenia—Methotrexate—colon cancer	0.000374	0.00066	CcSEcCtD
Bicalutamide—Pruritus—Methotrexate—colon cancer	0.000369	0.000651	CcSEcCtD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000361	0.0061	CbGpPWpGaD
Bicalutamide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000359	0.00607	CbGpPWpGaD
Bicalutamide—Diarrhoea—Methotrexate—colon cancer	0.000357	0.00063	CcSEcCtD
Bicalutamide—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	0.000349	0.0059	CbGpPWpGaD
Bicalutamide—Dizziness—Methotrexate—colon cancer	0.000345	0.000609	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000342	0.00579	CbGpPWpGaD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000342	0.00579	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—colon cancer	0.00034	0.00575	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—colon cancer	0.000336	0.00569	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000336	0.00569	CbGpPWpGaD
Bicalutamide—Vomiting—Methotrexate—colon cancer	0.000332	0.000585	CcSEcCtD
Bicalutamide—Rash—Methotrexate—colon cancer	0.000329	0.00058	CcSEcCtD
Bicalutamide—Dermatitis—Methotrexate—colon cancer	0.000329	0.00058	CcSEcCtD
Bicalutamide—Headache—Methotrexate—colon cancer	0.000327	0.000577	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—CDKN1A—colon cancer	0.000325	0.0055	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000324	0.00548	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—colon cancer	0.000313	0.00529	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—CCND1—colon cancer	0.000312	0.00528	CbGpPWpGaD
Bicalutamide—Nausea—Methotrexate—colon cancer	0.00031	0.000547	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—EP300—colon cancer	0.00031	0.00524	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—CTNNB1—colon cancer	0.000309	0.00523	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—CDKN1A—colon cancer	0.000302	0.0051	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—EP300—colon cancer	0.000287	0.00486	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—BRAF—colon cancer	0.00028	0.00474	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—SRC—colon cancer	0.000279	0.00472	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CDH1—colon cancer	0.000274	0.00464	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—HNF4A—colon cancer	0.000273	0.00461	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—colon cancer	0.000273	0.00461	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—colon cancer	0.00027	0.00456	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000247	0.00418	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—EGFR—colon cancer	0.000245	0.00414	CbGpPWpGaD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000238	0.00403	CbGpPWpGaD
Bicalutamide—AR—Coregulation of Androgen receptor activity—AKT1—colon cancer	0.000235	0.00397	CbGpPWpGaD
Bicalutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—colon cancer	0.000229	0.00387	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CASP3—colon cancer	0.00021	0.00355	CbGpPWpGaD
Bicalutamide—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	0.000209	0.00353	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—CASP3—colon cancer	0.000205	0.00346	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CCND1—colon cancer	0.000204	0.00346	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CTNNB1—colon cancer	0.000202	0.00342	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—CTNNB1—colon cancer	0.000197	0.00334	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—EP300—colon cancer	0.000188	0.00318	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.000187	0.00317	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—colon cancer	0.000187	0.00317	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—EP300—colon cancer	0.000183	0.0031	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—VEGFA—colon cancer	0.000178	0.00301	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	0.000174	0.00294	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—VEGFA—colon cancer	0.000174	0.00294	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—AKT1—colon cancer	0.000174	0.00294	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	0.000169	0.00286	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	0.000168	0.00284	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CA7—colon cancer	0.000166	0.00281	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MYC—colon cancer	0.000164	0.00277	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	0.000164	0.00277	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—EGFR—colon cancer	0.00016	0.00271	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	0.000156	0.00264	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CA7—colon cancer	0.000153	0.00258	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.000152	0.00256	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—KRAS—colon cancer	0.000151	0.00256	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CA7—colon cancer	0.000151	0.00256	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.000148	0.0025	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.000136	0.0023	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.000136	0.00229	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—TP53—colon cancer	0.000135	0.00228	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000133	0.00225	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—HNF4A—colon cancer	0.000131	0.00222	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	0.000126	0.00212	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—PPARG—colon cancer	0.000118	0.002	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	0.000115	0.00195	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—AKT1—colon cancer	0.000114	0.00192	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	0.000112	0.00189	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ODC1—colon cancer	0.000101	0.0017	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CHST5—colon cancer	0.000101	0.0017	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CA7—colon cancer	9.99e-05	0.00169	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	9.42e-05	0.00159	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CHST5—colon cancer	9.26e-05	0.00157	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ODC1—colon cancer	9.26e-05	0.00157	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ODC1—colon cancer	9.18e-05	0.00155	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CHST5—colon cancer	9.18e-05	0.00155	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—MYC—colon cancer	6.75e-05	0.00114	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ODC1—colon cancer	6.05e-05	0.00102	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CHST5—colon cancer	6.05e-05	0.00102	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PPARG—colon cancer	5.7e-05	0.000964	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.15e-05	0.000703	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.79e-05	0.000641	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.27e-05	0.000553	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—MYC—colon cancer	3.25e-05	0.00055	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.98e-05	0.000504	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.72e-05	0.00046	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ABCB1—colon cancer	2.66e-05	0.00045	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—TYMS—colon cancer	2.61e-05	0.000442	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.48e-05	0.000419	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ABCB1—colon cancer	2.45e-05	0.000414	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ABCB1—colon cancer	2.43e-05	0.00041	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—TYMS—colon cancer	2.4e-05	0.000406	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—TYMS—colon cancer	2.38e-05	0.000403	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—AKT1—colon cancer	2.25e-05	0.000381	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.01e-05	0.00034	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PPARG—colon cancer	1.85e-05	0.000313	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.83e-05	0.00031	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PPARG—colon cancer	1.7e-05	0.000288	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PPARG—colon cancer	1.69e-05	0.000285	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ABCB1—colon cancer	1.6e-05	0.000271	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TYMS—colon cancer	1.57e-05	0.000266	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTGS2—colon cancer	1.46e-05	0.000246	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTGS2—colon cancer	1.34e-05	0.000226	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTGS2—colon cancer	1.33e-05	0.000224	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—EP300—colon cancer	1.21e-05	0.000205	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—EP300—colon cancer	1.11e-05	0.000188	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PPARG—colon cancer	1.11e-05	0.000188	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—EP300—colon cancer	1.1e-05	0.000187	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CA—colon cancer	8.96e-06	0.000151	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTGS2—colon cancer	8.75e-06	0.000148	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CA—colon cancer	8.24e-06	0.000139	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CA—colon cancer	8.17e-06	0.000138	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—AKT1—colon cancer	7.32e-06	0.000124	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—EP300—colon cancer	7.28e-06	0.000123	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—AKT1—colon cancer	6.73e-06	0.000114	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—AKT1—colon cancer	6.67e-06	0.000113	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CA—colon cancer	5.39e-06	9.11e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—AKT1—colon cancer	4.4e-06	7.44e-05	CbGpPWpGaD
